No Data
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Shares Fly 52% But Investors Aren't Buying For Growth
ReanGene (688217.SH) zhejiang Dahelth, a shareholder, reduced its holdings by 0.5576 million shares. The shareholding period has expired.
Raygene (688217.SH) announced that the company received a notice from zhejiang Dajian, a shareholder, on September 27, 2024...
Rayon Genomics 2024 Semi-Annual Report
Summary of Ruion Genomics 2024 Semi-Annual Report
Ruian Genetics (688217.SH) released its performance for the first half of the year, with a net income of 9.2218 million yuan, a decrease of 43.20%.
Genon Gene (688217.SH) released its 2024 semi-annual report, with a revenue of 0.135 billion...
Geneplus (688217.SH): net income for the first half of the year was 9.2218 million yuan, a year-on-year decrease of 43.2%.
On August 29th, Gralon announced that it achieved a total operating revenue of 0.135 billion yuan in the first half of 2024, with a year-on-year growth of 5.66%. The net income attributable to the shareholders of the parent company was 9.2218 million yuan, a year-on-year decrease of 43.2%. The basic earnings per share was 0.17 yuan.
No Data
No Data